UBS Group »

Calidi Biotherapeutics shares owned by UBS Group

Quarter-by-quarter ownership of Calidi Biotherapeutics shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Calidi Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Calidi Biotherapeutics held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Calidi Biotherapeutics by UBS Group

Quarter filed Position value Share count Share price at filing
2025-09-30 $3.9k 2.6k 1.52

More positions owned by UBS Group

Spdr S&p 500 Etf Tr Tr Unit (SPY)
NVIDIA Corporation (NVDA)
Microsoft Corporation (MSFT)
Apple (AAPL)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Amazon (AMZN)
Broadcom (AVGO)
Meta Platforms Cl A (META)
Alphabet Cap Stk Cl A (GOOGL)
JPMorgan Chase & Co. (JPM)
Alphabet Cap Stk Cl C (GOOG)
Ubs Group SHS (UBS)
Tesla Motors (TSLA)
Ishares Tr Russell 2000 Etf (IWM)
Visa Com Cl A (V)

View all positions for UBS Group

Top funds holding Calidi Biotherapeutics

HighTower Advisors
Vanguard Group
Geode Capital Management
Belpointe Asset Management
Warberg Asset Management
Rs Crum
UBS Group
Highbridge Capital Management
Finepoint Capital
Apollo Management Holdings
Royal Bank of Canada
Barrett & Company
Advisor Group Holdings
FMR
Tradewinds Capital Management

View all funds holding Calidi Biotherapeutics